![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FibroGen Initiates Phase 2/3 Trial in Italy of Pamrevlumab for Severe COVID-19
FibroGen Initiates Phase 2/3 Trial in Italy of Pamrevlumab for Severe COVID-19
FibroGen has launched a phase 2/3 trial in Italy to evaluate pulmonary fibrosis treatment pamrevlumab in severe COVID-19 patients.
The trial will include 68 hospitalized patients who will receive either pamrevlumab or standard of care.
The company also plans to initiate two phase 2 trials in the U.S. to assess pamrevlumab vs. standard of care in patients with severe COVID-19.
Upcoming Events
-
18Jul
-
21Oct